Gary L. Keeney mostly deals with Internal medicine, Endometrial cancer, Surgery, Pathology and Oncology. His work focuses on many connections between Internal medicine and other disciplines, such as Gastroenterology, that overlap with his field of interest in Endometrium and Carcinoma. His Endometrial cancer research integrates issues from Hysterectomy, Lymphadenectomy, Primary tumor, Metastasis and Prospective cohort study.
His Pathology research includes themes of Chromosome 13 and Breast cancer. The Oncology study combines topics in areas such as Odds ratio, Tissue microarray and Bioinformatics. The various areas that Gary L. Keeney examines in his Stage study include Disease and Ovary.
His scientific interests lie mostly in Internal medicine, Pathology, Endometrial cancer, Oncology and Surgery. His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology. His work in Pathology addresses issues such as Ovary, which are connected to fields such as Disease.
His Endometrial cancer study combines topics from a wide range of disciplines, such as Hysterectomy, Lymphadenectomy, Lymph node, Metastasis and Adjuvant therapy. His Oncology research is multidisciplinary, incorporating elements of Serous fluid, Survival analysis, Hazard ratio, Breast cancer and Tissue microarray. His studies deal with areas such as Cohort and Urology as well as Surgery.
His primary areas of investigation include Internal medicine, Oncology, Endometrial cancer, Pathology and Serous fluid. His studies link Gene expression with Internal medicine. His Oncology study combines topics in areas such as Immunohistochemistry, Cancer research, Clinical trial, Chemotherapy and Ovarian cancer.
His biological study spans a wide range of topics, including Stage, Sentinel lymph node, Lymphadenectomy and Metastasis. His work carried out in the field of Pathology brings together such families of science as Fluorescence in situ hybridization and Gene rearrangement. He has researched Serous fluid in several fields, including Ovarian carcinoma and Ovarian tumor.
His primary scientific interests are in Cohort, Oncology, Internal medicine, Pathology and Lymphadenectomy. His research in Cohort intersects with topics in Immunohistochemistry, Tissue microarray and Carcinoma. His Oncology study which covers Clinical trial that intersects with Survival analysis.
In general Internal medicine study, his work on Debulking and Cancer often relates to the realm of Subtyping, thereby connecting several areas of interest. His work deals with themes such as Fluorescence in situ hybridization and Immunophenotyping, which intersect with Pathology. He combines subjects such as Stage IIIC, Sentinel lymph node, Progression-free survival and Endometrial cancer with his study of Lymphadenectomy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?
Andrea Mariani;Maurice J. Webb;Gary L. Keeney;Michael G. Haddock.
American Journal of Obstetrics and Gynecology (2000)
Folate receptor alpha as a tumor target in epithelial ovarian cancer
Kimberly R. Kalli;Ann L. Oberg;Gary L. Keeney;Teresa J.H. Christianson.
Gynecologic Oncology (2008)
Sentinel Lymph Node Biopsy With Metastasis: Can Axillary Dissection Be Avoided in Some Patients With Breast Cancer?
Carol Reynolds;Rosemarie Mick;John H. Donohue;Clive S. Grant.
Journal of Clinical Oncology (1999)
Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy
Robert L. Giuntoli;Daniel S. Metzinger;Connie S. Dimarco;Stephen S. Cha.
Gynecologic Oncology (2003)
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
Weiva Sieh;Martin Köbel;Teri A Longacre;David D Bowtell;David D Bowtell.
Lancet Oncology (2013)
Human Epithelial Ovarian Cancer Allelotype
W. Cliby;S. Ritland;L. Hartmann;M. Dodson.
Cancer Research (1993)
Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Evanthia Galanis;Lynn C. Hartmann;William A. Cliby;Harry J. Long.
Cancer Research (2010)
Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
Gottfried E. Konecny;Chen Wang;Habib Hamidi;Boris Winterhoff.
Journal of the National Cancer Institute (2014)
HER‐2/neu expression: A major prognostic factor in endometrial cancer
David J. Hetzel;Timothy O. Wilson;Gary L. Keeney;Patrick C. Roche.
Gynecologic Oncology (1992)
Genetic Analysis of Early- versus Late-Stage Ovarian Tumors
Viji Shridhar;Ajay Pandita;Rajeswari Avula;Julie Staub.
Cancer Research (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: